Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.
David J. Kuter(Harvard University), Janet L. Nichol(Amgen (United States)), Craig M. Kessler(Georgetown University), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Frank T. Slovick(Hematology Oncology Associates), James B. Bussel(Cornell University), Howard A. Liebman(Keck Hospital of USC), Francis M. Senecal(Northwest Medical Specialties), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Matthew Guo(Eisai (United States)), Reggie Kelly(Amgen (United States))
Cited by 5
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k